MENU
ADAP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Adaptimmune Therapeutics (ADAP) Ownership - Who owns Adaptimmune Therapeutics?
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
75.78M
P/E Ratio
N/A
Total Cash
186.09M
Projected Growth
N/A
Total Debt
74.5M
Revenue
175.04M
Risk (Beta)
2.81
Dividend Yield
N/A
Total Cash/Share
0.70
Total Debt/Equity
N/A
Revenue/Share
0.70 USD as % of share price
Fundamentals
ADAP
Capitalization
75.8M
P/E Ratio
N/A
Risk (Beta)
2.81
Dividend Yield
N/A
Total Cash
186M
Total Cash/Share
0.70
Total Debt
74.5M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.70%
Revenue
175M
ROE
N/A
Book Value
80M
P/B Ratio
5.92
Cash Flow
N/A
Earnings
-0.17
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
2.08M
Current Ratio
3.85
Current Revenue Per Employee
91093.54
Dividends Per Share - Security
N/A
EBITDA
-55.9M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-14.50
Shares Held By Institutions
68.2M
Shares Outstanding - Current
265M
Total Liabilities
237M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-49.675
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a manufacturer of vaccines and cancer immunotherapy products
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com